As of November 6, 2026, Connect Biopharma Holdings Ltd is a publicly traded company (Nasdaq: CNTB). The largest holder reporting an active stake on Schedule 13D is Panacea Innovation Limited, at 21.2%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Wubin Pan (9.6%), Zheng Wei (9%), Ikarian Capital, LLC (6.9%) (Schedule 13D/A, April 1, 2026).
Is this your company?
About to sign with, pay or invest in Connect Biopharma Holdings Ltd? See the free Snapshot first.
Free to see. No signup.
Is Connect Biopharma Holdings Ltd a real, registered company?
- Connect Biopharma Holdings Ltd files with the SEC under CIK 1835268 (its SEC filings).
- Its shares are listed under the ticker CNTB on Nasdaq (SEC company record).
- Incorporated in E9; business address in San Diego, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Connect Biopharma Holdings Ltd in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Braden M Leonard (filed 2026-10-06).
Who are Connect Biopharma Holdings Ltd's owners and officers?
Connect Biopharma Holdings Ltd: business address in San Diego, California; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-11-03).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-11-03 | Qiming Corporate Gp V, LTD. | 2.9% |
| Schedule 13G, 2026-10-06 | Braden M Leonard | 6.77% |
| Schedule 13G/A, 2026-08-14 | Wei Zheng | 4% |
| Schedule 13G/A, 2026-08-14 | Ikarian Capital, LLC | 6.9% |
| Schedule 13G/A, 2026-05-15 | Wei Zheng | 6.2% |
| Schedule 13G, 2026-04-14 | Wubin Pan | 9.6% |
| Schedule 13D/A, 2026-04-01 | Panacea Innovation Limited | 21.2% |
| Schedule 13G, 2026-02-17 | Ikarian Capital, LLC | 8.8% |
| Schedule 13G/A, 2026-02-17 | Zheng Wei | 9% |
| Schedule 13G/A, 2026-02-17 | Wubin Pan | 10.8% |
| Schedule 13G/A, 2025-11-28 | Wei Zheng | 9.9% |
| Schedule 13D/A, 2025-11-26 | Panacea Innovation Limited | 21.5% |
Questions about who owns Connect Biopharma Holdings Ltd
Who owns Connect Biopharma Holdings Ltd?
On this page, 5 holders' latest ownership filings report 5% or more of Connect Biopharma Holdings Ltd: Panacea Innovation Limited (21.2%, Schedule 13D/A, filed 2026-04-01), Wubin Pan (9.6%, Schedule 13G, filed 2026-04-14), Zheng Wei (9%, Schedule 13G/A, filed 2026-02-17), Ikarian Capital, LLC (6.9%, Schedule 13G/A, filed 2026-08-14) and Braden M Leonard (6.77%, Schedule 13G, filed 2026-10-06).
Who are the largest shareholders of Connect Biopharma Holdings Ltd?
By the share each holder's latest filing reports, the largest holders of Connect Biopharma Holdings Ltd on this page are Panacea Innovation Limited (21.2%), Wubin Pan (9.6%) and Zheng Wei (9%).
When did Panacea Innovation Limited buy into Connect Biopharma Holdings Ltd?
The filings give report dates, not purchase dates. The earliest filing from Panacea Innovation Limited on this page is the Schedule 13D/A, filed 2025-11-26, reporting 21.5%; its latest, Schedule 13D/A filed 2026-04-01, reports 21.2%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Connect Biopharma Holdings Ltd?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Connect Biopharma Holdings Ltd: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Connect Biopharma Holdings Ltd covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Connect Biopharma Holdings Ltd shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 13,310,000 shares (21.1% of shares outstanding), held indirectly (the form names the holder only in its footnotes) (Form 4, 2026-06-02).
- , the chief executive and a director: 224,034 shares (0.36% of shares outstanding), 95,147 held directly and 128,887 indirectly (Form 3, 2026-03-16).
- , the president: 215,739 shares (0.34% of shares outstanding) (Form 3, 2026-03-16).
- , a director: 91,554 shares (0.15% of shares outstanding) (Form 4, 2026-10-01).
- , the president and finance: 45,189 shares (0.07% of shares outstanding) (Form 3, 2026-03-16).
Shares outstanding: 62,974,309 as of 2026-07-31, from the company's latest SEC cover page.
How much has Connect Biopharma Holdings Ltd raised?
No fundraising or offering filing from Connect Biopharma Holdings Ltd is on file with us.
Keep reading
More on Connect Biopharma Holdings Ltd and the records around it.
Connect Biopharma Holdings Ltd elsewhere on the record
- 5%+ stake filings Nov 2026
Companies that share a holder
- Panacea Innovation Limited also filed stake reports on 3 other companies: Atara Biotherapeutics, Inc. (May 2026), CASI Pharmaceuticals, Inc. (Dec 2025), Adagene Inc. (Nov 2025)
- BML Investment Partners, L.P. also filed stake reports on 15 other companies: LENZ Therapeutics, Inc. (Nov 2026), Seer, Inc. (Nov 2026), Outset Medical, Inc. (Oct 2026)
- Ikarian Capital, LLC also filed stake reports on 22 other companies: Quoin Pharmaceuticals Ltd. (Oct 2026), Galera Therapeutics, Inc. (Aug 2026), InMed Pharmaceuticals Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/connect-biopharma